聚焦卒中神经保护新方向，麦科医药MT200605Ⅱ期临床研究完成数据库锁定
MICOT
点击蓝字 关注我们
Slide to view different languages
滑动查看不同语言
近日，由麦科医药（02335.HK）自主研发的创新药MT200605，用于急性缺血性卒中治疗的II期临床研究正式完成数据库锁定。这意味着，全部受试者的临床数据已完成收集、核查与审核，研究正式进入揭盲、统计分析和临床报告撰写阶段，为后续III期确证性研究奠定关键基础。
卒中：每12秒就有一人新发
急性缺血性卒中，俗称“脑梗”，是由于脑部动脉严重狭窄或闭塞导致局部脑组织缺血、缺氧性坏死的临床综合征。据权威数据显示，我国每年新发脑卒中约180万人，相当于每12秒就有一人发病，每21秒就有一人因病离世。
急性缺血性卒中病理机制复杂。受治疗时间窗、适用人群等因素限制，即使接受并实现再灌注治疗，部分患者仍可能面临持续性神经损伤及神经功能恢复不足——说话不清、半身不遂、记忆力下降等问题可能长期存在。如何加强神经保护、改善功能预后，仍是亟待解决的临床难题。
从“病灶”出发设计药物
区别于传统的单一靶点药物，麦科医药一直坚持“疾病机制导向”的源头创新。MT200605为一款小分子静脉注射液，能高效清除氧自由基，并选择性激活TrkB受体。其独特之处，在于它不做“临时修补”，而是从疾病源头双管齐下。
MT200605作用机制
一方面“保护”——抑制神经元凋亡、减轻兴奋性毒性、拮抗炎症反应减少细胞死亡，这叫被动保护。
另一方面“重建”——改善突触可塑性、促进神经再生，从上游重启神经细胞自身的内源性修复程序，这叫主动修复。
一“护”一“修”协同作用，同时干预上游信号传导和下游氧化/能量衰竭环节，既减轻当下损伤，又为长期功能恢复铺路——让神经细胞有能力“活得下来、修复得好”。
360例患者，5.5个月高效完成入组
MT200605的II期研究是一项多中心、随机、双盲、安慰剂对照临床试验，共入组360例急性缺血性卒中患者。从首例患者入组到全部入组完成，仅用时约5.5个月。入组结束后，研究团队高效完成了数据清理、医学审核、不良事件核查等锁库前准备工作，确保了研究质量和数据可靠性。
这一系列节点的顺利达成，也体现了麦科医药在多中心临床研究组织、跨团队协同和项目管理方面的综合能力。
下一步：揭盲、分析、决策
数据库锁定后，MT200605将进入揭盲和统计分析阶段。麦科医药将与统计专家、临床研究中心紧密协作，全面评估药物的有效性、安全性和获益风险比，并根据结果制定后续III期确证性研究方案。
创新药研发是一条漫长而艰难的路，需要扎实的科学根基和对患者需求的深刻理解。未来，麦科医药将继续坚持“从疾病机制出发，解决未满足临床需求”的研发理念，以患者需求为核心，稳步推进MT200605的研发进程，努力为卒中患者带来新的治疗希望。
MICOT
Micot Pharma (02335.HK) recently completed database lock for the Phase II trial of its independently developed innovative drug MT200605 in acute ischemic stroke. This milestone confirms that all participant data have been collected, verified, and reviewed. The study has now entered unblinding, statistical analysis, and clinical study report preparation, laying a critical foundation for the subsequent Phase III confirmatory study.
Stroke: One New Case Every 12 Seconds
Acute ischemic stroke, commonly known as cerebral infarction, is a clinical syndrome caused by focal brain tissue ischemia, hypoxia, and necrosis due to severe stenosis or occlusion of a cerebral artery. According to authoritative data, approximately 1.8 million new strokes occur in China each year—equivalent to one new case every 12 seconds and one stroke-related death every 21 seconds.
The pathophysiology of acute ischemic stroke is complex. Because of limitations in treatment windows and patient eligibility, even after reperfusion therapy and successful reperfusion, some patients may still experience persistent neurological injury and inadequate functional recovery. Speech impairment, hemiplegia, and memory decline may persist long term. Enhancing neuroprotection and improving functional outcomes therefore remain urgent clinical challenges.
Drug Design Starting from the Lesion
Unlike conventional single-target drugs, Micot Pharma has consistently pursued disease mechanism-guided innovation. MT200605 is a small-molecule intravenous formulation that efficiently scavenges oxygen free radicals and selectively activates TrkB receptors. Its distinctive feature is that, rather than providing a “temporary fix,” it targets the disease at its source through two complementary mechanisms.
Mechanism of Action of MT200605
On the one hand, it provides protection by inhibiting neuronal apoptosis, reducing excitotoxicity, and counteracting inflammatory responses to reduce cell death—an approach known as passive protection.
On the other hand, it promotes restoration by improving synaptic plasticity and promoting neuroregeneration, thereby reactivating neurons’ endogenous repair programs upstream—an approach known as active repair.
These complementary actions—protection and repair—simultaneously target upstream signaling and downstream oxidative stress and energy failure. By reducing immediate injury and supporting long-term functional recovery, MT200605 is designed to help neurons survive and repair effectively.
360 Patients Enrolled in 5.5 Months
The Phase II study of MT200605 was a multicenter, randomized, double-blind, placebo-controlled trial enrolling 360 patients with acute ischemic stroke. From first patient enrollment to completion of enrollment, the process took only approximately 5.5 months. After enrollment, the study team efficiently completed pre-lock activities, including data cleaning, medical review, and adverse event verification, to ensure study quality and data reliability.
The successful completion of these milestones also demonstrates Micot Pharma’s capabilities in multicenter trial coordination, cross-functional collaboration, and project management.
Next Steps: Unblinding, Analysis, and Decision-Making
Following database lock, the MT200605 study will proceed to unblinding and statistical analysis. Micot Pharma will work closely with biostatisticians and participating clinical sites to comprehensively assess the drug’s efficacy, safety, and benefit-risk profile and, based on the results, develop the subsequent Phase III confirmatory study protocol.
Innovative drug development is a long and challenging journey requiring a solid scientific foundation and a deep understanding of patient needs. Looking ahead, Micot Pharma will continue to uphold its R&D philosophy of “starting from disease mechanisms to address unmet clinical needs.” With patient needs at the core, the Company will steadily advance MT200605 development and strive to bring new therapeutic hope to patients with stroke.
MICOT
详情
奋斗为本、求是创新、协作共赢
